These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38806774)

  • 1. Metabolic dysfunction-associated fatty liver disease and heavy alcohol consumption increase mortality:A nationwide study.
    Cho SH; Kim S; Oh R; Kim JY; Lee YB; Jin SM; Hur KY; Kim G; Kim JH
    Hepatol Int; 2024 May; ():. PubMed ID: 38806774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential risk of 23 site-specific incident cancers and cancer-related mortality among patients with metabolic dysfunction-associated fatty liver disease: a population-based cohort study with 9.7 million Korean subjects.
    Chung GE; Yu SJ; Yoo JJ; Cho Y; Lee KN; Shin DW; Kim YJ; Yoon JH; Han K; Cho EJ
    Cancer Commun (Lond); 2023 Aug; 43(8):863-876. PubMed ID: 37337385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic dysfunction-associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality.
    van Kleef LA; de Knegt RJ; Brouwer WP
    Hepatology; 2023 Mar; 77(3):942-948. PubMed ID: 35776631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different minimal alcohol consumption in male and female individuals with metabolic dysfunction-associated fatty liver disease.
    Zhu Y; Xu X; Fan Z; Ma X; Rui F; Ni W; Hu X; Gu Q; Shi J; Wu C; Yeo YH; Li J
    Liver Int; 2024 Mar; 44(3):865-875. PubMed ID: 38263792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
    Zhang YC; Lyu ZY; Ma B; Li LM; Wang W; Sheng C; Dai HJ; Huang YB; Song FF; Song FJ; Chen KX
    Hepatol Int; 2022 Aug; 16(4):835-845. PubMed ID: 35701716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of alcohol consumption on metabolic dysfunction-associated fatty liver disease development and remission: A longitudinal cohort study.
    Sogabe M; Okahisa T; Kagawa M; Kashihara T; Fujmoto S; Kawaguchi T; Yokoyama R; Kagemoto K; Tanaka H; Kida Y; Tomonari T; Kawano Y; Sato Y; Nakasono M; Takayama T
    Eur J Clin Invest; 2024 Apr; ():e14221. PubMed ID: 38634705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
    Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of alcohol on newly developed metabolic dysfunction-associated fatty liver disease in both sexes: A longitudinal study.
    Sogabe M; Okahisa T; Kagawa M; Ueda H; Kagemoto K; Tanaka H; Kida Y; Tomonari T; Taniguchi T; Okamoto K; Miyamoto H; Sato Y; Nakasono M; Takayama T
    Clin Nutr; 2023 May; 42(5):810-816. PubMed ID: 37043935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
    Kim D; Konyn P; Sandhu KK; Dennis BB; Cheung AC; Ahmed A
    J Hepatol; 2021 Dec; 75(6):1284-1291. PubMed ID: 34380057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Stroke With Metabolic Dysfunction-Associated Fatty Liver Disease With and Without CKD.
    Li Y; Wu S; Gao J; Zhang Y; Zuo Y; Tian X; Chen S; Xing A; Wang A; He Y
    Am J Kidney Dis; 2024 Apr; 83(4):477-488. PubMed ID: 37838141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease.
    Younossi ZM; Stepanova M; Ong J; Yilmaz Y; Duseja A; Eguchi Y; El Kassas M; Castellanos-Fernandez M; George J; Jacobson IM; Bugianesi E; Wong VW; Arrese M; de Ledinghen V; Romero-Gomez M; Mendez-Sanchez N; Ahmed A; Wong R; Papatheodoridis G; Serfaty L; Younossi I; Nader F; Ziayee M; Afendy A;
    Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1625-1633.e1. PubMed ID: 30476585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
    Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
    J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of metabolic phenotype and alcohol consumption on mortality risk in metabolic dysfunction-associated fatty liver disease: a population-based cohort study.
    Charatcharoenwitthaya P; Karaketklang K; Aekplakorn W
    Sci Rep; 2024 Jun; 14(1):12663. PubMed ID: 38830939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
    Moon JH; Kim W; Koo BK; Cho NH;
    Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease.
    Staufer K; Huber-Schönauer U; Strebinger G; Pimingstorfer P; Suesse S; Scherzer TM; Paulweber B; Ferenci P; Stimpfl T; Yegles M; Datz C; Trauner M
    J Hepatol; 2022 Oct; 77(4):918-930. PubMed ID: 35605744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of the Metabolic Dysfunction-Associated Fatty Liver Disease with Serum Uric Acid-to-Creatinine Ratio.
    Han AL; Lee HK
    Metab Syndr Relat Disord; 2022 Sep; 20(7):370-376. PubMed ID: 35796698
    [No Abstract]   [Full Text] [Related]  

  • 17. Lean or diabetic subtypes predict increased all-cause and disease-specific mortality in metabolic-associated fatty liver disease.
    Chung GE; Yu SJ; Yoo JJ; Cho Y; Lee KN; Shin DW; Kim D; Kim YJ; Yoon JH; Han K; Cho EJ
    BMC Med; 2023 Jan; 21(1):4. PubMed ID: 36600263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study.
    Kim KS; Hong S; Ahn HY; Park CY
    Diabetes Metab J; 2023 Mar; 47(2):220-231. PubMed ID: 36631994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations between metabolic dysfunction-associated fatty liver disease and extrahepatic cancers: a cohort in China.
    Yuan X; Wang X; Wu S; Chen S; Wang Y; Wang J; Lu Y; Sun Y; Fu Q; Wang L
    Hepatobiliary Surg Nutr; 2023 Oct; 12(5):671-681. PubMed ID: 37886198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The bidirectional impacts of alcohol consumption and MAFLD for progressive fatty liver disease.
    Kulkarni AV; Sarin SK
    Ther Adv Endocrinol Metab; 2023; 14():20420188231178370. PubMed ID: 37323163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.